Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
Journal of Clinical Oncology · 2024-12 · 42 (34) · 4029-4039
DOI: 10.1200/jco.23.02747 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2024-12. Verfasst von James Chih-Hsin Yang und 21 weiteren Autor:innen. Beteiligte Einrichtung: National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan. Hauptthemen laut MEDLINE: Pemetrexed, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 153-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR -mutant, metastatic non–small cell lung cancer (NSCLC); however, most patients experience disease progression. We report results from the randomized, double-blind, phase III KEYNOTE-789 study of pemetrexed and platinum–based chemotherapy with or without pembrolizumab for TKI-resistant, EGFR -mutant, metastatic nonsquamous NSCLC (ClinicalTrials.gov identifier: NCT03515837 ). METHODS Adults with pathologically confirmed stage IV nonsquamous NSCLC, documented DEL19 or L858R EGFR mutation, and progression after EGFR-TKI treatment were randomly assigned 1:1 to 35 cycles of pembrolizumab 200 mg or placebo once every 3 weeks plus four cycles of pemetrexed and carboplatin or cisplatin once every 3 weeks and then maintenance pemetrexed. Dual primary end points were progression-free survival (PFS) and overall survival (OS). Final PFS testing was completed at the second interim analysis (IA2; data cutoff, December 3, 2021); OS was tested at final analysis (FA; data cutoff, January 17, 2023). Efficacy boundaries were one-sided P = .0117 for PFS and OS. RESULTS Four hundred ninety-two patients were randomly assigned to pembrolizumab plus chemotherapy (n = 245) or placebo plus chemotherapy (n = 247). At IA2, the median PFS was 5.6 months for pembrolizumab plus chemotherapy versus 5.5 months for placebo plus chemotherapy (hazard ratio [HR], 0.80 [95% CI, 0.65 to 0.97]; P = .0122). At FA, the median OS was 15.9 versus 14.7 months, respectively (HR, 0.84 [95% CI, 0.69 to 1.02]; P = .0362). Grade ≥3 treatment-related adverse events occurred in 43.7% of pembrolizumab plus chemotherapy recipients versus 38.6% of placebo plus chemotherapy recipients. CONCLUSION Addition of pembrolizumab to chemotherapy in patients with TKI-resistant, EGFR -mutant, metastatic nonsquamous NSCLC did not significantly prolong PFS or OS versus placebo plus chemotherapy in KEYNOTE-789.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.
- Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
- Seoul National University Bundang Hospital, Seoul, South Korea.
- Zhejiang Cancer Hospital, Hangzhou, China.
- Istituto Europeo di Oncologia, IRCCS, Milan, Italy.
- Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
ORCID-Profile: James Chih-Hsin Yang, Dae Ho Lee, Eiji Iwama, Takako Inoue, Jerónimo Rodríguez-Cid, Cheng-Ta Yang, Maurice Pérol, Ki Hyeong Lee, Gregory J Riely, Yiwen Luo, Shun Lu
Förderung
- NCI NIH HHS
Zitieren
APA
Yang, J. C., Lee, D. H., Lee, J. S., Fan, Y., de Marinis, F., Iwama, E., Inoue, T., Rodríguez-Cid, J., Zhang, L., Yang, C. T., de la Mora Jimenez, E., Zhou, J., Pérol, M., Lee, K. H., Vicente, D., Ichihara, E., Riely, G. J., Luo, Y., Chirovsky, D., …, & Lu, S. (2024). Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer. Journal of Clinical Oncology, 42(34), 4029-4039. https://doi.org/10.1200/jco.23.02747
Vancouver
Yang JC, Lee DH, Lee JS, Fan Y, de Marinis F, Iwama E, et al. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer. Journal of Clinical Oncology. 2024;42(34):4029-4039. doi:10.1200/jco.23.02747
BibTeX
@article{Yang2024,
author = {Yang, James Chih-Hsin and Lee, Dae Ho and Lee, Jong-Seok and Fan, Yun and de Marinis, Filippo and Iwama, Eiji and Inoue, Takako and Rodríguez-Cid, Jerónimo and Zhang, Li and Yang, Cheng-Ta and de la Mora Jimenez, Emmanuel and Zhou, Jianying and Pérol, Maurice and Lee, Ki Hyeong and Vicente, David and Ichihara, Eiki and Riely, Gregory J and Luo, Yiwen and Chirovsky, Diana and Pietanza, M Catherine and Bhagwati, Niyati and Lu, Shun},
title = {Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {34},
pages = {4029--4039},
doi = {10.1200/jco.23.02747}
}
EUVIMED